CRISPR Therapeutics (CRSP) Tops Q3 EPS by 58c

CRISPR Therapeutics (NASDAQ: CRSP) reported Q3 EPS of ($1.41), $0.58 better than the analyst estimate of ($1.99).

For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• ICICI Bank (ICICIBC:IN) (IBN) PT Raised to INR2,000 at Goldman Sachs
• Geberit AG (GEBN:SW) (GBERY) PT Raised to CHF712 at Jefferies